On-Chip Detection of the Biomarkers for Neurodegenerative Diseases: Technologies and Prospects

Overview

Journal Micromachines (Basel)

Publisher MDPI

Date 2020 Jul 2

PMID 32605280

Citations 1

Authors

Chao Song

Suya Que

Lucas Heimer

Long Que

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD), Parkinson's disease (PD) and glaucoma are all regarded as neurodegenerative diseases (neuro-DDs) because these diseases are highly related to the degeneration loss of functions and death of neurons with aging. The conventional diagnostic methods such as neuroimaging for these diseases are not only expensive but also time-consuming, resulting in significant financial burdens for patients and public health challenge for nations around the world. Hence early detection of neuro-DDs in a cost-effective and rapid manner is critically needed. For the past decades, some chip-based detection technologies have been developed to address this challenge, showing great potential in achieving point-of-care (POC) diagnostics of neuro-DDs. In this review, chip-based detection of neuro-DDs' biomarkers enabled by different transducing mechanisms is evaluated.

Citing Articles

Silicon-Based Biosensors: A Critical Review of Silicon's Role in Enhancing Biosensing Performance.

Muhammad W, Song J, Kim S, Ahmed F, Cho E, Lee H Biosensors (Basel). 2025; 15(2).

PMID: 39997021 PMC: 11852904. DOI: 10.3390/bios15020119.

A Review on Integrated ZnO-Based SERS Biosensors and Their Potential in Detecting Biomarkers of Neurodegenerative Diseases.

Colnita A, Toma V, Brezestean I, Tahir M, Dina N Biosensors (Basel). 2023; 13(5).

PMID: 37232860 PMC: 10216625. DOI: 10.3390/bios13050499.

References

Duran R, Barrero F, Morales B, Luna J, Ramirez M, Vives F . Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord. 2010; 25(4):489-93. DOI: 10.1002/mds.22928. View

Quigley H, Pease M, Kerrigan D, Mitchell R . Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci. 2000; 41(3):741-8. View

Middleton E, Rhoades E . Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys J. 2010; 99(7):2279-88. PMC: 3042580. DOI: 10.1016/j.bpj.2010.07.056. View

Star A, Tu E, Niemann J, Gabriel J, Joiner C, Valcke C . Label-free detection of DNA hybridization using carbon nanotube network field-effect transistors. Proc Natl Acad Sci U S A. 2006; 103(4):921-6. PMC: 1347966. DOI: 10.1073/pnas.0504146103. View

Sempionatto J, Brazaca L, Garcia-Carmona L, Bolat G, Campbell A, Martin A . Eyeglasses-based tear biosensing system: Non-invasive detection of alcohol, vitamins and glucose. Biosens Bioelectron. 2019; 137:161-170. PMC: 8372769. DOI: 10.1016/j.bios.2019.04.058. View

Chou I, Benford M, Beier H, Cote G, Wang M, Jing N . Nanofluidic biosensing for beta-amyloid detection using surface enhanced Raman spectroscopy. Nano Lett. 2008; 8(6):1729-35. PMC: 2587305. DOI: 10.1021/nl0808132. View

Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O . Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017; 52:196-213. DOI: 10.1016/j.neurobiolaging.2016.02.034. View

Preische O, Schultz S, Apel A, Kuhle J, Kaeser S, Barro C . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25(2):277-283. PMC: 6367005. DOI: 10.1038/s41591-018-0304-3. View

Timurdogan E, Alaca B, Kavakli I, Urey H . MEMS biosensor for detection of Hepatitis A and C viruses in serum. Biosens Bioelectron. 2011; 28(1):189-94. DOI: 10.1016/j.bios.2011.07.014. View

10.

Zhang T, He Y, Wei J, Que L . Nanostructured optical microchips for cancer biomarker detection. Biosens Bioelectron. 2012; 38(1):382-8. DOI: 10.1016/j.bios.2012.06.029. View

11.

Zhang Y, Guo Y, Xianyu Y, Chen W, Zhao Y, Jiang X . Nanomaterials for ultrasensitive protein detection. Adv Mater. 2013; 25(28):3802-19. DOI: 10.1002/adma.201301334. View

12.

Gervais L, De Rooij N, Delamarche E . Microfluidic chips for point-of-care immunodiagnostics. Adv Mater. 2011; 23(24):H151-76. DOI: 10.1002/adma.201100464. View

13.

Hampel H, Blennow K . CSF tau and β-amyloid as biomarkers for mild cognitive impairment. Dialogues Clin Neurosci. 2011; 6(4):379-90. PMC: 3181816. View

14.

Song L, Lachno D, Hanlon D, Shepro A, Jeromin A, Gemani D . A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics. Alzheimers Res Ther. 2016; 8(1):58. PMC: 5160015. DOI: 10.1186/s13195-016-0225-7. View

15.

de Mello A, Beard N . Dealing with real samples: sample pre-treatment in microfluidic systems. Lab Chip. 2004; 3(1):11N-19N. DOI: 10.1039/b301019h. View

16.

MacBeath G . Protein microarrays and proteomics. Nat Genet. 2002; 32 Suppl:526-32. DOI: 10.1038/ng1037. View

17.

Hagan S, Martin E, Enriquez-de-Salamanca A . Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. EPMA J. 2016; 7:15. PMC: 4942926. DOI: 10.1186/s13167-016-0065-3. View

18.

Gagni P, Sola L, Cretich M, Chiari M . Development of a high-sensitivity immunoassay for amyloid-beta 1-42 using a silicon microarray platform. Biosens Bioelectron. 2013; 47:490-5. DOI: 10.1016/j.bios.2013.03.077. View

19.

Sommer A, Tielsch J, Katz J, Quigley H, Gottsch J, Javitt J . Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991; 109(8):1090-5. DOI: 10.1001/archopht.1991.01080080050026. View

20.

Dickson D . Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012; 2(8). PMC: 3405828. DOI: 10.1101/cshperspect.a009258. View